Leading Anti-Cancer Drugs and Associated Market 2013-2023
Cancer treatments - here's your guide to R&D and sales potentials
Do you want to assess the future of cancer medicines? Visiongain's updated report gives you revenue predictions there from 2013, helping you stay ahead. You find financial data, R&D trends, opportunities, and outlooks.
In that work you see forecasted sales to 2023 at overall world market, submarket, product, and national level. You also assess emerging trends, technologies, and expected drugs.
You see what shapes that industry and find its revenue prospects
Discover, then, what the future holds for anti-cancer products. Read on to explore that industry and see what its future market could be worth.
Forecasts to 2023 and other analyses show you commercial potentials
Besides revenue forecasting to 2023, you find historical data, growth rates, and market shares. You assess quantitative and qualitative analysis, business news, outlooks, and developments (R&D). You also gain 114 tables, 47 charts, and three interviews.
Is finding data for cancer treatment a challenge? Our work lets you investigate the most promising and lucrative parts of applied oncology, helping you stay ahead in knowledge. That way, you reduce your risk of missing out. Finding data you need has just got easier.
Many opportunities remain for cancer-treating drugs. Now see how you can benefit your research, analyses, and decisions there.
The following sections show, then, how you benefit from our new investigation and analysis.
Discover outlooks for the world market and submarkets
Along with prediction of overall world market value to 2023, our report shows you revenue forecasting of four submarkets at world level:
See forecasts for the leading 25 cancer-treating drugs
How will leading drugs perform to 2023 at world level? Our study forecasts individual revenues of the top 25 anti-cancer agents, including these products:
You find geographical revenue predictions too.
Leading national markets - where lie highest revenues and growth?
Developments worldwide expand the cancer drugs market, especially rising demand for medicines in emerging countries. China, India, Russia, and Brazil underpin revenue growth.
In developed and developing countries, opportunities for pharma companies will occur from 2013. See where and how.
Our analyses show you individual revenue forecasts to 2023 for 11 national markets:
Research and development - assess innovation, trends, and possibilities
What's happening in oncological R&D? You see trends for treating these cancers:
For large companies and specialty pharma firms there exist many opportunities. Our study explains, discussing issues to help your work. Also, see what shapes the market from 2013.
What affects the industry and market for anti-cancer drugs?
Our report discusses issues and events affecting that industry and market from 2013, including these:
See, then, what the future holds.
Leading companies in cancer treatment and 2017 market value
From 2013, new treatments hold great potential for investment, technological advances and high revenues. Our report predicts the world market for anti-cancer agents will reach $116.5bn in 2017, and expand further to 2023.
Our analyses show you what technologies, products, and organisations hold greatest potential. They cover these leading companies, among others:
Nine ways Leading Anti-Cancer Drugs and Associated Market 2013-2023 helps you
In particular, then, our investigation gives you the following knowledge:
That work gives independent analysis. You receive business intelligence found only in our report, seeing where prospects are most rewarding.
With our study you are less likely to fall behind in knowledge or miss opportunity. See there how you could benefit your research, analyses, and decisions, also saving time.
Discover potential now in anti-cancer medicines and see what you can gain.
Ordering now lets you discover opportunities and predictions for cancer treatments
Our new study is for everyone analysing the industry and market for pharmaceutical biotechnology and cancer medicines. There you find data, trends, opportunities, and predictions. Avoid missing out - please order our report now.
Do you want to assess the future of cancer medicines? Visiongain's updated report gives you revenue predictions there from 2013, helping you stay ahead. You find financial data, R&D trends, opportunities, and outlooks.
In that work you see forecasted sales to 2023 at overall world market, submarket, product, and national level. You also assess emerging trends, technologies, and expected drugs.
You see what shapes that industry and find its revenue prospects
Discover, then, what the future holds for anti-cancer products. Read on to explore that industry and see what its future market could be worth.
Forecasts to 2023 and other analyses show you commercial potentials
Besides revenue forecasting to 2023, you find historical data, growth rates, and market shares. You assess quantitative and qualitative analysis, business news, outlooks, and developments (R&D). You also gain 114 tables, 47 charts, and three interviews.
Is finding data for cancer treatment a challenge? Our work lets you investigate the most promising and lucrative parts of applied oncology, helping you stay ahead in knowledge. That way, you reduce your risk of missing out. Finding data you need has just got easier.
Many opportunities remain for cancer-treating drugs. Now see how you can benefit your research, analyses, and decisions there.
The following sections show, then, how you benefit from our new investigation and analysis.
Discover outlooks for the world market and submarkets
Along with prediction of overall world market value to 2023, our report shows you revenue forecasting of four submarkets at world level:
- Immunotherapies
- Targeted therapies
- Hormone-based agents
- Chemotherapies.
See forecasts for the leading 25 cancer-treating drugs
How will leading drugs perform to 2023 at world level? Our study forecasts individual revenues of the top 25 anti-cancer agents, including these products:
- Rituxan
- Herceptin
- Avastin
- Gleevec
- Revlimid
- Alimta
- Velcade.
You find geographical revenue predictions too.
Leading national markets - where lie highest revenues and growth?
Developments worldwide expand the cancer drugs market, especially rising demand for medicines in emerging countries. China, India, Russia, and Brazil underpin revenue growth.
In developed and developing countries, opportunities for pharma companies will occur from 2013. See where and how.
Our analyses show you individual revenue forecasts to 2023 for 11 national markets:
- US
- Japan
- Germany, France, UK, Italy, and Spain (EU5)
- Brazil, Russia, India, and China (BRIC).
Research and development - assess innovation, trends, and possibilities
What's happening in oncological R&D? You see trends for treating these cancers:
- Bladder
- Brain
- Breast
- Cervix
- Gut
- Kidney
- Leukaemia
- Liver
- Lung.
- Lymphoma
- Multiple myeloma
- Ovary
- Pancreas
- Prostate
- Sarcoma and skin
- Stomach
- Other cancers.
For large companies and specialty pharma firms there exist many opportunities. Our study explains, discussing issues to help your work. Also, see what shapes the market from 2013.
What affects the industry and market for anti-cancer drugs?
Our report discusses issues and events affecting that industry and market from 2013, including these:
- Epidemiology - incidence, prevalence, mortality, and survival
- Tumour (tumor) resistance, heterogeneity, and other medical challenges
- Personalised medicine, live licensing, and theranostics
- Cost-effectiveness, pricing, and reimbursement
- Payers and healthcare policy.
- Monoclonal antibodies (mAbs), cancer vaccines, and other technologies
- Efficacy, toxicity, and alternative treatments
- Biosimilars (follow-on-protein products) and generics
- Pharmacogenomics and genome screening
- Biomarkers and diagnostics.
See, then, what the future holds.
Leading companies in cancer treatment and 2017 market value
From 2013, new treatments hold great potential for investment, technological advances and high revenues. Our report predicts the world market for anti-cancer agents will reach $116.5bn in 2017, and expand further to 2023.
Our analyses show you what technologies, products, and organisations hold greatest potential. They cover these leading companies, among others:
- Roche
- Novartis
- Celgene
- AstraZeneca
- Eli Lilly
- Merck & Co.
Nine ways Leading Anti-Cancer Drugs and Associated Market 2013-2023 helps you
In particular, then, our investigation gives you the following knowledge:
- Revenue to 2023 for the world anti-cancer drugs market - discover that industry's overall sales potential
- Revenues to 2023 for 4 world-level submarkets - investigate the potential of its components, finding the most promising places for investments and revenues
- Revenues to 2023 for 25 leading products - find sales outlooks for top brands, seeing how they can compete and succeed
- Forecasts to 2023 for 11 leading national markets in the Americas, Europe, and Asia - discover the best countries for revenues and potential growth
- Assessments of leading companies - hear about participants' activities, capabilities, results, and outlooks
- Review of R&D in oncology - explore progress in research and development, finding technological and clinical possibilities
- Interviews with authorities in the field - discover debates and opinions to help you stay ahead
- Analysis of what stimulates and restrains that industry and market - assess challenges and strengths, helping you compete and get advantages
- Competition and opportunities - investigate what shapes that market's future, including ways to develop business.
That work gives independent analysis. You receive business intelligence found only in our report, seeing where prospects are most rewarding.
With our study you are less likely to fall behind in knowledge or miss opportunity. See there how you could benefit your research, analyses, and decisions, also saving time.
Discover potential now in anti-cancer medicines and see what you can gain.
Ordering now lets you discover opportunities and predictions for cancer treatments
Our new study is for everyone analysing the industry and market for pharmaceutical biotechnology and cancer medicines. There you find data, trends, opportunities, and predictions. Avoid missing out - please order our report now.
1. EXECUTIVE SUMMARY
1.1 Overview of Findings
1.2 Chapter Breakdown
1.3 Research and Analysis Methods
1.4 Scope of the Report
2. INTRODUCTION TO CANCER TREATMENT
2.1 The Physiology of Cancer - Causes and Effects
2.1.1 Uncontrolled Growth
2.1.2 Dedifferentiation
2.1.3 Invasiveness and Metastasis
2.1.4 Causes of Cancer
2.2 The Incidence and Prevalence of Cancer - Rapid Global Growth
2.2.1 Incidence
2.2.2 Mortality
2.2.3 Survival - Improving Odds
2.2.3.1 The Developed World
2.2.3.2 The Developing World - More Must Be Done
2.3 Treating Tumours - How Can We Fight Back?
2.3.1 Chemotherapy - The Traditional Treatment
2.3.2 Hormone Therapies
2.3.3 Immunotherapy - A Magic Bullet
2.3.3.1 Monoclonal Antibodies (mAbs)
2.3.3.2 Cancer Vaccines
2.3.3.3 Non-Specific Immunotherapies
2.3.4 Targeted Therapies
2.3.5 Differentiating Agents
3. WORLD ANTI-CANCER DRUG MARKET, 2013-2023
3.1 Immunotherapies' Market Domination in 2012
3.2 Global Anti-Cancer Drugs Market Forecast, 2013-2023
3.3 Immunotherapy Market Forecast, 2013-2023 -The Fastest Growing Anti-Cancer Segment
3.4 Targeted Therapy Market Forecast, 2013-2023 - Another Robust Driver of Growth
3.5 Hormone Therapy Forecast, 2013-2023 - Dependably Solid
3.6 Chemotherapy Market Forecast, 2013-2023 - A Major Contributor
4. LEADING NATIONAL MARKETS, 2013-2023
4.1 Anti-Cancer Drugs - Leading National Markets, 2012
4.2 The US Anti-Cancer Drug Market, 2013-2023 - Continued Leadership or Terminal Decline?
4.3 The Japanese Anti-Cancer Drug Market, 2013-2023
4.4 The Leading Five Anti-Cancer Drug Markets in the EU (EU5), 2013-2023 - Serious Competitors to the US Market?
4.5 Anti-Cancer Drug Markets in BRIC Countries, 2013-2023 - Awakening Sleeping Giants?
4.5.1 Brazil, 2013-2023- BRIC's Smallest Market
4.5.2 Russia, 2013-2023 - Rising Cancer Rates Drive Growth
4.5.3 India, 2013-2023 - Lucrative Opportunity for Growth
4.5.4 China, 2013-2023 - Can This Market Fulfil Vast Potential?
5. TOP 25 ANTI-CANCER DRUGS: MARKET PROSPECTS, 2013-2023
5.1 Rituxan/MabThera (Roche) - The World's Leader
5.1.1 Rituxan Sales, 2012
5.1.2 Competition Facing Rituxan - David vs. Goliath
5.1.3 Rituxan Sales Forecast, 2013-2023
5.2 Herceptin (Roche)
5.2.1 Herceptin Sales, 2012
5.2.2 Competition Facing Herceptin - A Tough Act to Follow
5.2.3 Rituxan Sales Forecast, 2013-2023
5.3 Avastin (Roche) - Slowing Growth
5.3.1 Avastin Sales, 2012
5.3.2 Competition Facing Avastin - Many Newer Options
5.3.3 Avastin Sales Forecast, 2013-2023
5.4 Gleevec (Novartis)
5.4.1 Gleevec Sales, 2012
5.4.2 Competition Facing Gleevec - Looming Generic Challengers
5.4.3 Gleevec Sales Forecast, 2013-2023
5.5 Revlimid (Celgene) - Celgene's Main Revenue Generator
5.5.1 Revlimid Sales, 2012
5.5.2 Competition Facing Revlimid - A Crowded Market
5.5.3 Revlimid Sales Forecast, 2013-2023 - A Long-Term Leader?
5.6 Alimta (Eli Lilly)
5.6.1 Alimta Sales, 2012
5.6.2 Competition Facing Alimta - Strong Challengers Await
5.6.3 Alimta Sales Forecast, 2013-2023 - Revenue Erosion Looming
5.7 Velcade (Takeda/J&J)
5.7.1 Velcade Sales, 2012
5.7.2 Competition Facing Velcade - A New Product to Worry About
5.7.3 Velcade Sales Forecast, 2013-2023 - A Dependable Revenue Generator
5.8 Gardasil (Merck & Co.) - One Vaccine to Dominate?
5.8.1 Gardasil Sales, 2012
5.8.2 Competition Facing Gardasil - Only One Challenger That Matters
5.8.3 Gardasil Sales Forecast, 2013-2023 - Merck's Revenue Generator
5.9 Xeloda (Roche)
5.9.1 Xeloda Sales, 2012
5.9.2 Competition Facing Xeloda - Is It Up To The Challenge?
5.9.3 Xeloda Sales Forecast, 2013-2023
5.10 Tarceva (Roche)
5.10.1Tarceva Sales, 2012
5.10.2 Competition Facing Tarceva - A Number of Other Options
5.10.3 Tarceva Sales Forecast, 2013-2023 - An Excellent Return
5.11 Sutent (Pfizer) - A Replacement for Gleevec
5.11.1 Sutent Sales, 2012
5.11.2 Competition Facing Sutent
5.11.3 Sutent Sales Forecast, 2013-2023 - Solid Sales for Several More Years
5.12 Zoladex (AstraZeneca) - Prominent Hormone Therapy
5.12.1 Zoladex Sales, 2012
5.12.2 Competition Facing Zoladex
5.12.3 Zoladex Sales Forecast, 2013-2023
5.13 Sprycel (Bristol-Myers Squibb)
5.13.1 Sprycel Sales, 2012 - Rapid Growth
5.13.2 Competition Facing Sprycel
5.13.3 Sprycel Sales Forecast, 2013-2023 - How Long Will the Growth Last?
5.14 Nexavar (Bayer/Onyx)
5.14.1 Nexavar Sales, 2012- Stalled Growth?
5.14.2 Competition Facing Nexavar
5.14.3 Nexavar Sales Forecast, 2013-2023 - More Years of Success
5.15 Tasigna (Novartis)
5.15.1 Tasigna Sales, 2012 - Blockbuster Revenue
5.15.2 Competition Facing Tasigna
5.15.3 Tasigna Sales Forecast, 2013-2023 - A Multi-Billion Dollar Product?
5.16 Eloxatin (Sanofi)
5.16.1 Eloxatin Sales, 2012
5.16.2 Competition Facing Eloxatin - Looming Patent Expiry
5.16.3 Eloxatin Sales Forecast, 2013-2023
5.17 Temodar/Temodal (Merck & Co.)
5.17.1 Temodar Sales, 2012
5.17.2 Competition Facing Temodar
5.17.3 Temodar Sales Forecast, 2013-2023 - Generic Competition Awaits
5.18 Vidaza (Celgene)
5.18.1 Vidaza Sales, 2012
5.18.2 Competition Facing Vidaza - Generic Competitor a Matter of Time
5.18.3 Vidaza Sales Forecast, 2013-2023
5.19 Afinitor (Novartis) - A Breast Cancer Breakthrough
5.19.1 Afinitor Sales, 2012 - Another Success
5.19.2 Competition Facing Afinitor
5.19.3 Afinitor Sales Forecast, 2013-2023
5.20 Xgeva (Amgen)
5.20.1 Xgeva Sales, 2012- Massive Growth in Sales
5.20.2 Competition Facing Xgeva
5.20.3 Xgeva Sales Forecast, 2013-2023 - Expectations Are High
5.21 Taxotere (Sanofi)
5.21.1 Taxotere Sales, 2012 - How Rapid a Revenue Erosion?
5.21.2 Competition Facing Taxotere
5.21.3 Taxotere Sales Forecast, 2013-2023
5.22 Yervoy (Bristol-Myers Squibb)
5.22.1 Yervoy Sales, 2012 - Revenue Expansion Possible
5.22.3 Competition Facing Yervoy
5.22.3 Yervoy Sales Forecast, 2013-2023 - How Many Years of Growth Await?
5.23 Erbitux (Bristol-Myers Squibb)
5.23.1 Erbitux Sales, 2012
5.23.2 Competition Facing Erbitux
5.23.3 Erbitux Sales Forecast, 2013-2023 - Gradual Drop in Revenues Expected
5.24 Faslodex (AstraZeneca) - Zoladex's Counterpart
5.24.1 Faslodex Sales, 2012 - Europe and Japan Lead the Way
5.24.2 Competition Facing Faslodex
5.24.3 Faslodex Sales Forecast, 2013-2023
5.25 Treanda (Teva Pharmaceuticals)
5.25.1 Treanda Sales, 2012
5.25.2 Competition Facing Treanda
5.25.3 Treanda Sales Forecast, 2013-2023 - Stalled Revenue Growth?
6. DRUGS APPROVED 2012-2013: TOMORROW'S BLOCKBUSTERS?
6.1 FDA-Approved Treatments in 2013
6.1.1 Kadcyla (Roche): A Potential Game-Changer
6.1.1.1 Market Potential
6.1.2 Pomalyst (Celgene)
6.1.2.1 Market Potential: An Addition to a Crowded Market
6.2 FDA-Approved Treatments in 2012: Rise of the Targeted Therapies
6.2.1 Abraxane (Celgene)
6.2.1.1 Market Potential: A Lower-Cost Alternative to Existing Treatments
6.2.2 Afinitor (Novartis)
6.2.2.1 Market Potential: More Indications, Greater Revenues?
6.2.3 Bosulif (Pfizer): Pfizer's Answer to Novartis
6.2.3.1 Market Potential
6.2.4 Cometriq (Exelixis)
6.2.4.1 Market Potential: Welcome Addition to an Open Market
6.2.5 Erivedge (Roche): A Future Blockbuster?
6.2.5.1 Market Potential
6.2.6 Iclusig (Ariad Pharmaceuticals)
6.2.6.1 Market Potential: A Capable Alternative to Gleevec
6.2.7 Inlyta (Pfizer)
6.2.7.1 Market Potential: Just Another Tyrosine Kinase Inhibitor?
6.2.8 Krypolis (Onyx Pharmaceuticals)
6.2.8.1 Market Potential: Stiff Competition May Blunt Growth
6.2.9 Marqibo (Talon Therapeutics)
6.2.9.1 Market Potential
6.2.10 Perjeta (Roche)
6.2.10.1 Market Potential
6.2.11Stivarga (Bayer HealthCare Pharmaceuticals)
6.2.11.1 Market Potential: Another Option for Patients
6.2.12 Synribo (Teva Pharmaceuticals)
6.2.12.1 Market Potential: A Potential Cash Cow
6.2.13 Votrient (GlaxoSmithKline): GSK's Newest Entry
6.2.13.1 Market Potential
6.2.14 Xtandi (Medivation): Prostate Cancer's Newest Foe
6.2.14.1 Market Potential
6.2.15 Zaltrap (Sanofi):
6.2.15.1 Market Potential: Sanofi's Newest Anti-Cancer Winner?
7. LEADING COMPANIES FOR CANCER TREATMENTS, 2013
7.1 Anti-Cancer Drug Market Dominated by Six Companies
7.2 Roche - The World's Foremost Oncology Company
7.2.1 Oncology Pipeline - Investment in the Future
7.2.2 Future Directions in Cancer Treatment
7.3 Novartis - Tomorrow's Leader?
7.3.1 Oncology R&D Pipeline - What's the Potential?
7.3.2 Future Directions in Cancer Treatment
7.4 Celgene - Pressing Need to Diversify?
7.4.1 Oncology Pipeline - Safeguarding Celgene's Future
7.4.2 Future Directions in Cancer Treatment
7.5 AstraZeneca - A Well-Balanced Portfolio
7.5.1 Oncology Pipeline - Showing Promise
7.5.2 Future Directions in Cancer Treatment
7.6 Eli Lilly - How Strong is its Contribution to the Market?
7.6.1 Oncology Pipeline - What Potential Exists?
7.6.2 Future Directions in Cancer Treatment
7.7 Merck & Co. - Prominent in Vaccines
7.7.1 Oncology Pipeline - Greater Focus on Oncology
7.7.2 Future Directions in Cancer Treatment
8. R&D PIPELINES FOR CANCER TREATMENT
8.1 Bladder Cancer Drugs Under Development
8.1.1 Profile: EOquin (Allergan)
8.2 Brain Cancer Drugs Under Development
8.2.1 Profile: Rindopepimut (Celldex Therapeutics)
8.3 Breast Cancer Drugs Under Development
8.3.1 Afatinib (Boehringer Ingelheim)
8.4 Cervical Cancer Drugs Under Development
8.4.1 Profile: V503 (Merck & Co.)
8.5 Colorectal Cancer Drugs Under Development
8.5.1 Aptocine (Light Sciences Oncology)
8.6 Kidney Cancer Drugs Under Development
8.6.1 Rencarex (Wilex)
8.7 Leukaemia Drugs Under Development
8.7.1 Obinutuzumab (Roche)
8.8 Liver Cancer Drugs Under Development
8.8.1 Brivanib (Bristol-Myers Squibb)
8.9 Lung Cancer Drugs Under Development
8.9.1 BIBF 1120 (Boehringer Ingelheim)
8.10 Lymphoma Drugs Under Development
8.10.1 Inotuzumab Ozogamicin (Pfizer)
8.11 Multiple Myeloma Drugs Under Development
8.11.1 LBH589 (Novartis)
8.12 Ovarian Cancer Drugs Under Development
8.12.1 AMG 386 (Amgen)
8.13 Pancreatic Cancer Drugs Under Development
8.13.1 AMG 479 (Amgen)
8.14 Prostate Cancer Drugs Under Development
8.14.1 MDV-3100 (Astellas Pharma US/Medivation)
8.15 Sarcoma Drugs Under Development
8.15.1 Mifamurtide (Millennium Pharmaceuticals)
8.16 Skin Cancer Drugs Under Development
8.16.1 Allovectin (Vical)
8.17 Stomach Cancer Drugs Under Development
8.17.1 Ramucirumab (Eli Lilly/ImClone Systems)
8.18 Other Cancer Drugs Under Development
8.18.1 Lenvatinib (Eisai)
9. SWOT AND STEP ANALYSES, 2013
9.1 Strengths of the Industry and Market
9.1.1 High Profile of Cancer
9.1.2 Off-Label Prescriptions Common
9.1.3 Drug Development Incentives
9.2 Weaknesses of the Industry and Market
9.2.1 Tumour Resistance
9.2.2 Pricing-Out the Developing World?
9.3 Opportunities for the Industry and Market
9.3.1 Rising Incidence of Cancer
9.3.1.1 Ageing Populations
9.3.1.2 Smoking
9.3.1.3 Obesity
9.3.1.4 The Developing World
9.3.2 Personalised Medicine
9.3.3 Live Licensing
9.3.4 Convenient Drugs
9.4 Threats Facing the Industry and Market
9.4.1 The Cost-Effectiveness Debate
9.4.2 Governments: Leading Payers for Drugs
9.4.3 Efficacy, Toxicity and Alternative Treatments
9.5 Biosimilars and Generics: Opportunity or Threat?
9.6 Personalised Medicine
9.6.1 Cancer Heterogeneity
9.6.2 Pharmacogenomics
9.6.3 Genome Screening
9.6.4 Biomarkers and Diagnostics
9.6.5 Theranostics
10. RESEARCH INTERVIEWS
10.1 Interview with Dr Sidong Huang, Assistant Professor of Biochemistry at McGill University
10.1.1 On His Research Interests and their Utility in Anti-Cancer Drug Development
10.1.2 On the Evaluation of New Targets for Anti-Cancer Drugs
10.1.3 On Drug Resistance and Targeted Therapies
10.1.4 On the Future of Traditional Chemotherapy
10.1.5 On Future Developments in the Anti-Cancer Field
10.2 Interview with Dr Neil Butt, Director, Antitope Ltd.
10.2.1 On Immunogenicity in Therapeutic Proteins
10.2.2 On Antitope's Technologies to Assess and Reduce Immunogenicity
10.2.3 On an Alternative Way of Reducing Immunogenicity
10.2.4 On Biosimilars
10.2.5 On Future Developments in this Field
10.3 Interview with Dr Kent C. Osborne, Baylor College of Medicine
10.3.1 On Challenges in Developing Anti-Cancer Therapies
10.3.2 On Major Areas of Focus
10.3.3 On Cancer Vaccines
10.3.4 On Areas with Potential for Increased Revenue Generation
10.3.5 On the R&D Pipeline
10.3.6 On Difficulties Conducting Clinical Trials
11. CONCLUSIONS
11.1 Top 25 Drugs in the World Cancer Treatment Market
11.2 Immunotherapies - The Driving Force
11.2.1 Biosimilars Have Potential in Emerging Markets
11.3 The US- the Largest Anti-Cancer Drug Market
11.4 India and China Will be the Fastest-Growing National Markets
11.5 Personalised Medicine - the Future of Cancer Therapy
11.6 Anti-Cancer Drug Pipeline Remains Strong
11.7 Concluding Remarks
1.1 Overview of Findings
1.2 Chapter Breakdown
1.3 Research and Analysis Methods
1.4 Scope of the Report
2. INTRODUCTION TO CANCER TREATMENT
2.1 The Physiology of Cancer - Causes and Effects
2.1.1 Uncontrolled Growth
2.1.2 Dedifferentiation
2.1.3 Invasiveness and Metastasis
2.1.4 Causes of Cancer
2.2 The Incidence and Prevalence of Cancer - Rapid Global Growth
2.2.1 Incidence
2.2.2 Mortality
2.2.3 Survival - Improving Odds
2.2.3.1 The Developed World
2.2.3.2 The Developing World - More Must Be Done
2.3 Treating Tumours - How Can We Fight Back?
2.3.1 Chemotherapy - The Traditional Treatment
2.3.2 Hormone Therapies
2.3.3 Immunotherapy - A Magic Bullet
2.3.3.1 Monoclonal Antibodies (mAbs)
2.3.3.2 Cancer Vaccines
2.3.3.3 Non-Specific Immunotherapies
2.3.4 Targeted Therapies
2.3.5 Differentiating Agents
3. WORLD ANTI-CANCER DRUG MARKET, 2013-2023
3.1 Immunotherapies' Market Domination in 2012
3.2 Global Anti-Cancer Drugs Market Forecast, 2013-2023
3.3 Immunotherapy Market Forecast, 2013-2023 -The Fastest Growing Anti-Cancer Segment
3.4 Targeted Therapy Market Forecast, 2013-2023 - Another Robust Driver of Growth
3.5 Hormone Therapy Forecast, 2013-2023 - Dependably Solid
3.6 Chemotherapy Market Forecast, 2013-2023 - A Major Contributor
4. LEADING NATIONAL MARKETS, 2013-2023
4.1 Anti-Cancer Drugs - Leading National Markets, 2012
4.2 The US Anti-Cancer Drug Market, 2013-2023 - Continued Leadership or Terminal Decline?
4.3 The Japanese Anti-Cancer Drug Market, 2013-2023
4.4 The Leading Five Anti-Cancer Drug Markets in the EU (EU5), 2013-2023 - Serious Competitors to the US Market?
4.5 Anti-Cancer Drug Markets in BRIC Countries, 2013-2023 - Awakening Sleeping Giants?
4.5.1 Brazil, 2013-2023- BRIC's Smallest Market
4.5.2 Russia, 2013-2023 - Rising Cancer Rates Drive Growth
4.5.3 India, 2013-2023 - Lucrative Opportunity for Growth
4.5.4 China, 2013-2023 - Can This Market Fulfil Vast Potential?
5. TOP 25 ANTI-CANCER DRUGS: MARKET PROSPECTS, 2013-2023
5.1 Rituxan/MabThera (Roche) - The World's Leader
5.1.1 Rituxan Sales, 2012
5.1.2 Competition Facing Rituxan - David vs. Goliath
5.1.3 Rituxan Sales Forecast, 2013-2023
5.2 Herceptin (Roche)
5.2.1 Herceptin Sales, 2012
5.2.2 Competition Facing Herceptin - A Tough Act to Follow
5.2.3 Rituxan Sales Forecast, 2013-2023
5.3 Avastin (Roche) - Slowing Growth
5.3.1 Avastin Sales, 2012
5.3.2 Competition Facing Avastin - Many Newer Options
5.3.3 Avastin Sales Forecast, 2013-2023
5.4 Gleevec (Novartis)
5.4.1 Gleevec Sales, 2012
5.4.2 Competition Facing Gleevec - Looming Generic Challengers
5.4.3 Gleevec Sales Forecast, 2013-2023
5.5 Revlimid (Celgene) - Celgene's Main Revenue Generator
5.5.1 Revlimid Sales, 2012
5.5.2 Competition Facing Revlimid - A Crowded Market
5.5.3 Revlimid Sales Forecast, 2013-2023 - A Long-Term Leader?
5.6 Alimta (Eli Lilly)
5.6.1 Alimta Sales, 2012
5.6.2 Competition Facing Alimta - Strong Challengers Await
5.6.3 Alimta Sales Forecast, 2013-2023 - Revenue Erosion Looming
5.7 Velcade (Takeda/J&J)
5.7.1 Velcade Sales, 2012
5.7.2 Competition Facing Velcade - A New Product to Worry About
5.7.3 Velcade Sales Forecast, 2013-2023 - A Dependable Revenue Generator
5.8 Gardasil (Merck & Co.) - One Vaccine to Dominate?
5.8.1 Gardasil Sales, 2012
5.8.2 Competition Facing Gardasil - Only One Challenger That Matters
5.8.3 Gardasil Sales Forecast, 2013-2023 - Merck's Revenue Generator
5.9 Xeloda (Roche)
5.9.1 Xeloda Sales, 2012
5.9.2 Competition Facing Xeloda - Is It Up To The Challenge?
5.9.3 Xeloda Sales Forecast, 2013-2023
5.10 Tarceva (Roche)
5.10.1Tarceva Sales, 2012
5.10.2 Competition Facing Tarceva - A Number of Other Options
5.10.3 Tarceva Sales Forecast, 2013-2023 - An Excellent Return
5.11 Sutent (Pfizer) - A Replacement for Gleevec
5.11.1 Sutent Sales, 2012
5.11.2 Competition Facing Sutent
5.11.3 Sutent Sales Forecast, 2013-2023 - Solid Sales for Several More Years
5.12 Zoladex (AstraZeneca) - Prominent Hormone Therapy
5.12.1 Zoladex Sales, 2012
5.12.2 Competition Facing Zoladex
5.12.3 Zoladex Sales Forecast, 2013-2023
5.13 Sprycel (Bristol-Myers Squibb)
5.13.1 Sprycel Sales, 2012 - Rapid Growth
5.13.2 Competition Facing Sprycel
5.13.3 Sprycel Sales Forecast, 2013-2023 - How Long Will the Growth Last?
5.14 Nexavar (Bayer/Onyx)
5.14.1 Nexavar Sales, 2012- Stalled Growth?
5.14.2 Competition Facing Nexavar
5.14.3 Nexavar Sales Forecast, 2013-2023 - More Years of Success
5.15 Tasigna (Novartis)
5.15.1 Tasigna Sales, 2012 - Blockbuster Revenue
5.15.2 Competition Facing Tasigna
5.15.3 Tasigna Sales Forecast, 2013-2023 - A Multi-Billion Dollar Product?
5.16 Eloxatin (Sanofi)
5.16.1 Eloxatin Sales, 2012
5.16.2 Competition Facing Eloxatin - Looming Patent Expiry
5.16.3 Eloxatin Sales Forecast, 2013-2023
5.17 Temodar/Temodal (Merck & Co.)
5.17.1 Temodar Sales, 2012
5.17.2 Competition Facing Temodar
5.17.3 Temodar Sales Forecast, 2013-2023 - Generic Competition Awaits
5.18 Vidaza (Celgene)
5.18.1 Vidaza Sales, 2012
5.18.2 Competition Facing Vidaza - Generic Competitor a Matter of Time
5.18.3 Vidaza Sales Forecast, 2013-2023
5.19 Afinitor (Novartis) - A Breast Cancer Breakthrough
5.19.1 Afinitor Sales, 2012 - Another Success
5.19.2 Competition Facing Afinitor
5.19.3 Afinitor Sales Forecast, 2013-2023
5.20 Xgeva (Amgen)
5.20.1 Xgeva Sales, 2012- Massive Growth in Sales
5.20.2 Competition Facing Xgeva
5.20.3 Xgeva Sales Forecast, 2013-2023 - Expectations Are High
5.21 Taxotere (Sanofi)
5.21.1 Taxotere Sales, 2012 - How Rapid a Revenue Erosion?
5.21.2 Competition Facing Taxotere
5.21.3 Taxotere Sales Forecast, 2013-2023
5.22 Yervoy (Bristol-Myers Squibb)
5.22.1 Yervoy Sales, 2012 - Revenue Expansion Possible
5.22.3 Competition Facing Yervoy
5.22.3 Yervoy Sales Forecast, 2013-2023 - How Many Years of Growth Await?
5.23 Erbitux (Bristol-Myers Squibb)
5.23.1 Erbitux Sales, 2012
5.23.2 Competition Facing Erbitux
5.23.3 Erbitux Sales Forecast, 2013-2023 - Gradual Drop in Revenues Expected
5.24 Faslodex (AstraZeneca) - Zoladex's Counterpart
5.24.1 Faslodex Sales, 2012 - Europe and Japan Lead the Way
5.24.2 Competition Facing Faslodex
5.24.3 Faslodex Sales Forecast, 2013-2023
5.25 Treanda (Teva Pharmaceuticals)
5.25.1 Treanda Sales, 2012
5.25.2 Competition Facing Treanda
5.25.3 Treanda Sales Forecast, 2013-2023 - Stalled Revenue Growth?
6. DRUGS APPROVED 2012-2013: TOMORROW'S BLOCKBUSTERS?
6.1 FDA-Approved Treatments in 2013
6.1.1 Kadcyla (Roche): A Potential Game-Changer
6.1.1.1 Market Potential
6.1.2 Pomalyst (Celgene)
6.1.2.1 Market Potential: An Addition to a Crowded Market
6.2 FDA-Approved Treatments in 2012: Rise of the Targeted Therapies
6.2.1 Abraxane (Celgene)
6.2.1.1 Market Potential: A Lower-Cost Alternative to Existing Treatments
6.2.2 Afinitor (Novartis)
6.2.2.1 Market Potential: More Indications, Greater Revenues?
6.2.3 Bosulif (Pfizer): Pfizer's Answer to Novartis
6.2.3.1 Market Potential
6.2.4 Cometriq (Exelixis)
6.2.4.1 Market Potential: Welcome Addition to an Open Market
6.2.5 Erivedge (Roche): A Future Blockbuster?
6.2.5.1 Market Potential
6.2.6 Iclusig (Ariad Pharmaceuticals)
6.2.6.1 Market Potential: A Capable Alternative to Gleevec
6.2.7 Inlyta (Pfizer)
6.2.7.1 Market Potential: Just Another Tyrosine Kinase Inhibitor?
6.2.8 Krypolis (Onyx Pharmaceuticals)
6.2.8.1 Market Potential: Stiff Competition May Blunt Growth
6.2.9 Marqibo (Talon Therapeutics)
6.2.9.1 Market Potential
6.2.10 Perjeta (Roche)
6.2.10.1 Market Potential
6.2.11Stivarga (Bayer HealthCare Pharmaceuticals)
6.2.11.1 Market Potential: Another Option for Patients
6.2.12 Synribo (Teva Pharmaceuticals)
6.2.12.1 Market Potential: A Potential Cash Cow
6.2.13 Votrient (GlaxoSmithKline): GSK's Newest Entry
6.2.13.1 Market Potential
6.2.14 Xtandi (Medivation): Prostate Cancer's Newest Foe
6.2.14.1 Market Potential
6.2.15 Zaltrap (Sanofi):
6.2.15.1 Market Potential: Sanofi's Newest Anti-Cancer Winner?
7. LEADING COMPANIES FOR CANCER TREATMENTS, 2013
7.1 Anti-Cancer Drug Market Dominated by Six Companies
7.2 Roche - The World's Foremost Oncology Company
7.2.1 Oncology Pipeline - Investment in the Future
7.2.2 Future Directions in Cancer Treatment
7.3 Novartis - Tomorrow's Leader?
7.3.1 Oncology R&D Pipeline - What's the Potential?
7.3.2 Future Directions in Cancer Treatment
7.4 Celgene - Pressing Need to Diversify?
7.4.1 Oncology Pipeline - Safeguarding Celgene's Future
7.4.2 Future Directions in Cancer Treatment
7.5 AstraZeneca - A Well-Balanced Portfolio
7.5.1 Oncology Pipeline - Showing Promise
7.5.2 Future Directions in Cancer Treatment
7.6 Eli Lilly - How Strong is its Contribution to the Market?
7.6.1 Oncology Pipeline - What Potential Exists?
7.6.2 Future Directions in Cancer Treatment
7.7 Merck & Co. - Prominent in Vaccines
7.7.1 Oncology Pipeline - Greater Focus on Oncology
7.7.2 Future Directions in Cancer Treatment
8. R&D PIPELINES FOR CANCER TREATMENT
8.1 Bladder Cancer Drugs Under Development
8.1.1 Profile: EOquin (Allergan)
8.2 Brain Cancer Drugs Under Development
8.2.1 Profile: Rindopepimut (Celldex Therapeutics)
8.3 Breast Cancer Drugs Under Development
8.3.1 Afatinib (Boehringer Ingelheim)
8.4 Cervical Cancer Drugs Under Development
8.4.1 Profile: V503 (Merck & Co.)
8.5 Colorectal Cancer Drugs Under Development
8.5.1 Aptocine (Light Sciences Oncology)
8.6 Kidney Cancer Drugs Under Development
8.6.1 Rencarex (Wilex)
8.7 Leukaemia Drugs Under Development
8.7.1 Obinutuzumab (Roche)
8.8 Liver Cancer Drugs Under Development
8.8.1 Brivanib (Bristol-Myers Squibb)
8.9 Lung Cancer Drugs Under Development
8.9.1 BIBF 1120 (Boehringer Ingelheim)
8.10 Lymphoma Drugs Under Development
8.10.1 Inotuzumab Ozogamicin (Pfizer)
8.11 Multiple Myeloma Drugs Under Development
8.11.1 LBH589 (Novartis)
8.12 Ovarian Cancer Drugs Under Development
8.12.1 AMG 386 (Amgen)
8.13 Pancreatic Cancer Drugs Under Development
8.13.1 AMG 479 (Amgen)
8.14 Prostate Cancer Drugs Under Development
8.14.1 MDV-3100 (Astellas Pharma US/Medivation)
8.15 Sarcoma Drugs Under Development
8.15.1 Mifamurtide (Millennium Pharmaceuticals)
8.16 Skin Cancer Drugs Under Development
8.16.1 Allovectin (Vical)
8.17 Stomach Cancer Drugs Under Development
8.17.1 Ramucirumab (Eli Lilly/ImClone Systems)
8.18 Other Cancer Drugs Under Development
8.18.1 Lenvatinib (Eisai)
9. SWOT AND STEP ANALYSES, 2013
9.1 Strengths of the Industry and Market
9.1.1 High Profile of Cancer
9.1.2 Off-Label Prescriptions Common
9.1.3 Drug Development Incentives
9.2 Weaknesses of the Industry and Market
9.2.1 Tumour Resistance
9.2.2 Pricing-Out the Developing World?
9.3 Opportunities for the Industry and Market
9.3.1 Rising Incidence of Cancer
9.3.1.1 Ageing Populations
9.3.1.2 Smoking
9.3.1.3 Obesity
9.3.1.4 The Developing World
9.3.2 Personalised Medicine
9.3.3 Live Licensing
9.3.4 Convenient Drugs
9.4 Threats Facing the Industry and Market
9.4.1 The Cost-Effectiveness Debate
9.4.2 Governments: Leading Payers for Drugs
9.4.3 Efficacy, Toxicity and Alternative Treatments
9.5 Biosimilars and Generics: Opportunity or Threat?
9.6 Personalised Medicine
9.6.1 Cancer Heterogeneity
9.6.2 Pharmacogenomics
9.6.3 Genome Screening
9.6.4 Biomarkers and Diagnostics
9.6.5 Theranostics
10. RESEARCH INTERVIEWS
10.1 Interview with Dr Sidong Huang, Assistant Professor of Biochemistry at McGill University
10.1.1 On His Research Interests and their Utility in Anti-Cancer Drug Development
10.1.2 On the Evaluation of New Targets for Anti-Cancer Drugs
10.1.3 On Drug Resistance and Targeted Therapies
10.1.4 On the Future of Traditional Chemotherapy
10.1.5 On Future Developments in the Anti-Cancer Field
10.2 Interview with Dr Neil Butt, Director, Antitope Ltd.
10.2.1 On Immunogenicity in Therapeutic Proteins
10.2.2 On Antitope's Technologies to Assess and Reduce Immunogenicity
10.2.3 On an Alternative Way of Reducing Immunogenicity
10.2.4 On Biosimilars
10.2.5 On Future Developments in this Field
10.3 Interview with Dr Kent C. Osborne, Baylor College of Medicine
10.3.1 On Challenges in Developing Anti-Cancer Therapies
10.3.2 On Major Areas of Focus
10.3.3 On Cancer Vaccines
10.3.4 On Areas with Potential for Increased Revenue Generation
10.3.5 On the R&D Pipeline
10.3.6 On Difficulties Conducting Clinical Trials
11. CONCLUSIONS
11.1 Top 25 Drugs in the World Cancer Treatment Market
11.2 Immunotherapies - The Driving Force
11.2.1 Biosimilars Have Potential in Emerging Markets
11.3 The US- the Largest Anti-Cancer Drug Market
11.4 India and China Will be the Fastest-Growing National Markets
11.5 Personalised Medicine - the Future of Cancer Therapy
11.6 Anti-Cancer Drug Pipeline Remains Strong
11.7 Concluding Remarks
LIST OF TABLES
Table 2.1 Cancer-Treating Agents: Chemotherapies and Hormone Therapies, 2013
Table 2.2 Cancer-Treating Agents: Immunotherapies, Targeted Therapies and Differentiating Agents, 2013
Table 3.1 Global Anti-Cancer Market Sales ($bn), Annual Growth Rates (%) and Market Shares (%) by Segment, 2011 and 2012
Table 3.2 Global Anti-Cancer Market Forecast ($bn), 2012-2013
Table 3.3 Global Anti-Cancer Drug Market: Revenue Forecasts by Category ($bn), 2012-2023
Table 3.4 Global Anti-Cancer Market: Drivers and Restraints, 2013
Table 3.5 Global Immunotherapies Market ($bn), 2012
Table 3.6 Immunotherapy Market Forecast ($bn), 2012-2023
Table 3.7 Immunotherapy Market: Drivers and Restraints, 2013
Table 3.8 Global Targeted Therapies Market ($bn), 2012
Table 3.9 Targeted Therapies Market Forecast ($bn), 2012-2023
Table 3.10 Targeted Therapies Market: Drivers and Restraints, 2013
Table 3.11Hormone Therapy Market Forecast ($bn), 2012-2023
Table 3.12 Hormone Therapy Market: Drivers and Restraints, 2013
Table 3.13 Global Chemotherapies Market ($bn), 2012
Table 3.14 Chemotherapy Market Forecast ($bn), 2012-2023
Table 3.15 Chemotherapy Market: Drivers and Restraints, 2013
Table 4.1 Anti-Cancer Drug Market by Leading Country ($bn), 2012, 2017 and 2023
Table 4.2 Developed Markets: Drivers and Restraints, 2013
Table 4.3 Emerging Markets: Drivers and Restraints, 2013
Table 4.4 Global Anti-Cancer Drug Market: Forecasts by Leading Country ($bn), 2012-2023
Table 4.5 US Anti-Cancer Drug Market Forecast ($bn), 2012-2023
Table 4.6 Japanese Anti-Cancer Drug Market Forecast ($bn), 2012-2023
Table 4.7 The Leading 5 EU Anti-Cancer Drug Markets: Forecasts ($bn), 2012-2023
Table 4.8 BRIC Countries: Anti-Cancer Drug Markets: Forecasts ($bn), 2012-2023
Table 5.1 Top 25 Anti-Cancer Drugs: Sales ($bn) and Market Shares (%), 2012
Table 5.2 Top 5 Companies in the Anti-Cancer Drugs Market: Sales ($bn) and Market Shares (%), 2012
Table 5.3 Top 25 Anti-Cancer Drugs: Sales Forecasts ($bn), 2012-2023
Table 5.4 Top 25 Anti-Cancer Drugs: Sales Forecasts ($bn), 2012-2023 (Contd.)
Table 5.5 Top 25 Anti-Cancer Drugs: Sales Forecasts ($bn), 2012-2023 (Contd.)
Table 5.6 Rituxan Sales Forecast ($bn), 2012-2023
Table 5.7 Rituxan: Sales Drivers and Restraints, 2013
Table 5.8 Herceptin Sales Forecast ($bn), 2012-2023
Table 5.9 Herceptin: Sales Drivers and Restraints, 2013
Table 5.10 Avastin Sales Forecast ($bn), 2012-2023
Table 5.11 Avastin: Sales Drivers and Restraints, 2013
Table 5.12 Gleevec Sales Forecast ($bn), 2012-2023
Table 5.13 Gleevec: Sales Drivers and Restraints, 2013
Table 5.14 Revlimid Sales Forecast ($bn), 2012-2023
Table 5.15 Revlimid: Sales Drivers and Restraints, 2013
Table 5.16 Alimta Sales Forecast ($bn), 2012-2023
Table 5.17 Alimta: Sales Drivers and Restraints, 2013
Table 5.18 Velcade Sales Forecast ($bn), 2012-2023
Table 5.19 Velcade: Sales Drivers and Restraints, 2013
Table 5.20 Gardasil Sales Forecast ($bn), 2012-2023
Table 5.21 Gardasil: Sales Drivers and Restraints, 2013
Table 5.22 Xeloda Sales Forecast ($bn), 2012-2023
Table 5.23 Xeloda: Sales Drivers and Restraints, 2013
Table 5.24 Tarceva Sales Forecast ($bn), 2012-2023
Table 5.25 Tarceva: Sales Drivers and Restraints, 2013
Table 5.26 Sutent Sales Forecast ($bn), 2012-2023
Table 5.27 Sutent: Sales Drivers and Restraints, 2013
Table 5.28 Zoladex Sales Forecast ($bn), 2012-2023
Table 5.29 Zoladex: Sales Drivers and Restraints, 2013
Table 5.30 Sprycel Sales Forecast ($bn), 2012-2023
Table 5.31 Sprycel: Sales Drivers and Restraints, 2013
Table 5.32 Nexavar Sales Forecast ($bn), 2012-2023
Table 5.33 Nexavar: Sales Drivers and Restraints, 2013
Table 5.34 Tasigna Sales Forecast ($bn), 2012-2023
Table 5.35 Tasigna Sales Drivers and Restraints, 2013
Table 5.36 Eloxatin Sales Forecast ($bn), 2012-2023
Table 5.37 Eloxatin: Sales Drivers and Restraints, 2013
Table 5.38 Temodar Sales Forecast ($bn), 2012-2023
Table 5.39 Temodar Sales Drivers and Restraints, 2013
Table 5.40 Vidaza Sales Forecast ($bn), 2012-2023
Table 5.41 Vidaza Sales Drivers and Restraints, 2013
Table 5.42 Afinitor Sales Forecast ($bn), 2012-2023
Table 5.43 Afinitor Drivers and Restraints, 2013
Table 5.44 Xgeva Sales Forecast ($bn), 2012-2023
Table 5.45 Xgeva Drivers and Restraints, 2013
Table 5.46 Taxotere Sales Forecast ($bn), 2012-2023
Table 5.47 Taxotere: Sales Drivers and Restraints, 2013
Table 5.48 Yervoy Sales Forecast ($bn), 2012-2023
Table 5.49 Yervoy: Sales Drivers and Restraints, 2013
Table 5.50 Erbitux Sales Forecast ($bn), 2012-2023
Table 5.51 Erbitux: Sales Drivers and Restraints, 2013
Table 5.52 Faslodex Sales Forecast ($bn), 2012-2023
Table 5.53 Faslodex: Sales Drivers and Restraints, 2013
Table 5.54 Treanda Sales Forecast ($bn), 2012-2023
Table 5.55 Treanda: Sales Drivers and Restraints, 2013
Table 7.1 Anti-Cancer Drug Sales ($bn) and Market Shares (%) by Leading Company, 2012
Table 7.2 Roche Anti-Cancer Drugs: Sales ($bn), 2011-2012
Table 7.3 Selected Drugs from Roche Oncology Pipeline, 2012
Table 7.4 Novartis Anti-Cancer Drugs: Sales ($bn), 2011-2012
Table 7.5 Novartis Oncology Pipeline, 2012
Table 7.6 Celgene Anti-Cancer Drugs: Sales ($bn), 2011-2012
Table 7.7 Celgene Oncology Pipeline, 2012
Table 7.8 AstraZeneca Anti-Cancer Drugs: Sales ($bn), 2011-2012
Table 7.9 Selected Drugs from AstraZeneca Oncology Pipeline, 2012
Table 7.10 Eli Lilly Anti-Cancer Drugs: Sales ($bn), 2011-2012
Table 7.11 Selected Drugs from Eli Lilly Oncology Pipeline, 2012
Table 7.12 Merck & Co. Anti-Cancer Drugs: Sales ($bn), 2011-2012
Table 7.13 Merck & Co. Oncology Pipeline, 2012
Table 8.1 Cancer Medicines in Testing: Numbers by Therapeutic Area, 2012
Table 8.2 Bladder Cancer: Some Late Stage Drugs Under Development, 2012
Table 8.3 Brain Cancer: Some Late Stage Drugs Under Development, 2012
Table 8.4 Breast Cancer: Some Late Stage Drugs Under Development, 2012
Table 8.5 Cervical Cancer: Some Late Stage Drugs Under Development, 2012
Table 8.6 Colorectal Cancer: Some Late Stage Drugs Under Development, 2012
Table 8.7 Kidney Cancer: Some Late Stage Drugs Under Development, 2012
Table 8.8 Leukaemia: Some Late Stage Drugs Under Development, 2012
Table 8.9 Liver Cancer: Some Late Stage Drugs Under Development, 2012
Table 8.10 Lung Cancer: Some Late Stage Drugs Under Development, 2012
Table 8.11 Lymphoma: Some Late Stage Drugs Under Development, 2012
Table 8.12 Multiple Myeloma: Late Stage Drug Under Development, 2012
Table 8.13 Ovarian Cancer: Some Late Stage Drugs Under Development, 2012
Table 8.14 Pancreatic Cancer: Some Late Stage Drugs Under Development, 2012
Table 8.15 Prostate Cancer: Some Late Stage Drugs Under Development, 2012
Table 8.16 Sarcoma: Some Late Stage Drugs Under Development, 2012
Table 8.17 Skin Cancer: Some Late Stage Drugs Under Development, 2012
Table 8.18 Stomach Cancer: Some Late Stage Drugs Under Development, 2012
Table 8.19 Other Cancers: Some Late Stage Drugs Under Development, 2012
Table 9.1 SWOT Analysis of the Anti-Cancer Drugs Market, 2013
Table 9.2 STEP Analysis of the Anti-Cancer Drug Market, 2013
Table 2.1 Cancer-Treating Agents: Chemotherapies and Hormone Therapies, 2013
Table 2.2 Cancer-Treating Agents: Immunotherapies, Targeted Therapies and Differentiating Agents, 2013
Table 3.1 Global Anti-Cancer Market Sales ($bn), Annual Growth Rates (%) and Market Shares (%) by Segment, 2011 and 2012
Table 3.2 Global Anti-Cancer Market Forecast ($bn), 2012-2013
Table 3.3 Global Anti-Cancer Drug Market: Revenue Forecasts by Category ($bn), 2012-2023
Table 3.4 Global Anti-Cancer Market: Drivers and Restraints, 2013
Table 3.5 Global Immunotherapies Market ($bn), 2012
Table 3.6 Immunotherapy Market Forecast ($bn), 2012-2023
Table 3.7 Immunotherapy Market: Drivers and Restraints, 2013
Table 3.8 Global Targeted Therapies Market ($bn), 2012
Table 3.9 Targeted Therapies Market Forecast ($bn), 2012-2023
Table 3.10 Targeted Therapies Market: Drivers and Restraints, 2013
Table 3.11Hormone Therapy Market Forecast ($bn), 2012-2023
Table 3.12 Hormone Therapy Market: Drivers and Restraints, 2013
Table 3.13 Global Chemotherapies Market ($bn), 2012
Table 3.14 Chemotherapy Market Forecast ($bn), 2012-2023
Table 3.15 Chemotherapy Market: Drivers and Restraints, 2013
Table 4.1 Anti-Cancer Drug Market by Leading Country ($bn), 2012, 2017 and 2023
Table 4.2 Developed Markets: Drivers and Restraints, 2013
Table 4.3 Emerging Markets: Drivers and Restraints, 2013
Table 4.4 Global Anti-Cancer Drug Market: Forecasts by Leading Country ($bn), 2012-2023
Table 4.5 US Anti-Cancer Drug Market Forecast ($bn), 2012-2023
Table 4.6 Japanese Anti-Cancer Drug Market Forecast ($bn), 2012-2023
Table 4.7 The Leading 5 EU Anti-Cancer Drug Markets: Forecasts ($bn), 2012-2023
Table 4.8 BRIC Countries: Anti-Cancer Drug Markets: Forecasts ($bn), 2012-2023
Table 5.1 Top 25 Anti-Cancer Drugs: Sales ($bn) and Market Shares (%), 2012
Table 5.2 Top 5 Companies in the Anti-Cancer Drugs Market: Sales ($bn) and Market Shares (%), 2012
Table 5.3 Top 25 Anti-Cancer Drugs: Sales Forecasts ($bn), 2012-2023
Table 5.4 Top 25 Anti-Cancer Drugs: Sales Forecasts ($bn), 2012-2023 (Contd.)
Table 5.5 Top 25 Anti-Cancer Drugs: Sales Forecasts ($bn), 2012-2023 (Contd.)
Table 5.6 Rituxan Sales Forecast ($bn), 2012-2023
Table 5.7 Rituxan: Sales Drivers and Restraints, 2013
Table 5.8 Herceptin Sales Forecast ($bn), 2012-2023
Table 5.9 Herceptin: Sales Drivers and Restraints, 2013
Table 5.10 Avastin Sales Forecast ($bn), 2012-2023
Table 5.11 Avastin: Sales Drivers and Restraints, 2013
Table 5.12 Gleevec Sales Forecast ($bn), 2012-2023
Table 5.13 Gleevec: Sales Drivers and Restraints, 2013
Table 5.14 Revlimid Sales Forecast ($bn), 2012-2023
Table 5.15 Revlimid: Sales Drivers and Restraints, 2013
Table 5.16 Alimta Sales Forecast ($bn), 2012-2023
Table 5.17 Alimta: Sales Drivers and Restraints, 2013
Table 5.18 Velcade Sales Forecast ($bn), 2012-2023
Table 5.19 Velcade: Sales Drivers and Restraints, 2013
Table 5.20 Gardasil Sales Forecast ($bn), 2012-2023
Table 5.21 Gardasil: Sales Drivers and Restraints, 2013
Table 5.22 Xeloda Sales Forecast ($bn), 2012-2023
Table 5.23 Xeloda: Sales Drivers and Restraints, 2013
Table 5.24 Tarceva Sales Forecast ($bn), 2012-2023
Table 5.25 Tarceva: Sales Drivers and Restraints, 2013
Table 5.26 Sutent Sales Forecast ($bn), 2012-2023
Table 5.27 Sutent: Sales Drivers and Restraints, 2013
Table 5.28 Zoladex Sales Forecast ($bn), 2012-2023
Table 5.29 Zoladex: Sales Drivers and Restraints, 2013
Table 5.30 Sprycel Sales Forecast ($bn), 2012-2023
Table 5.31 Sprycel: Sales Drivers and Restraints, 2013
Table 5.32 Nexavar Sales Forecast ($bn), 2012-2023
Table 5.33 Nexavar: Sales Drivers and Restraints, 2013
Table 5.34 Tasigna Sales Forecast ($bn), 2012-2023
Table 5.35 Tasigna Sales Drivers and Restraints, 2013
Table 5.36 Eloxatin Sales Forecast ($bn), 2012-2023
Table 5.37 Eloxatin: Sales Drivers and Restraints, 2013
Table 5.38 Temodar Sales Forecast ($bn), 2012-2023
Table 5.39 Temodar Sales Drivers and Restraints, 2013
Table 5.40 Vidaza Sales Forecast ($bn), 2012-2023
Table 5.41 Vidaza Sales Drivers and Restraints, 2013
Table 5.42 Afinitor Sales Forecast ($bn), 2012-2023
Table 5.43 Afinitor Drivers and Restraints, 2013
Table 5.44 Xgeva Sales Forecast ($bn), 2012-2023
Table 5.45 Xgeva Drivers and Restraints, 2013
Table 5.46 Taxotere Sales Forecast ($bn), 2012-2023
Table 5.47 Taxotere: Sales Drivers and Restraints, 2013
Table 5.48 Yervoy Sales Forecast ($bn), 2012-2023
Table 5.49 Yervoy: Sales Drivers and Restraints, 2013
Table 5.50 Erbitux Sales Forecast ($bn), 2012-2023
Table 5.51 Erbitux: Sales Drivers and Restraints, 2013
Table 5.52 Faslodex Sales Forecast ($bn), 2012-2023
Table 5.53 Faslodex: Sales Drivers and Restraints, 2013
Table 5.54 Treanda Sales Forecast ($bn), 2012-2023
Table 5.55 Treanda: Sales Drivers and Restraints, 2013
Table 7.1 Anti-Cancer Drug Sales ($bn) and Market Shares (%) by Leading Company, 2012
Table 7.2 Roche Anti-Cancer Drugs: Sales ($bn), 2011-2012
Table 7.3 Selected Drugs from Roche Oncology Pipeline, 2012
Table 7.4 Novartis Anti-Cancer Drugs: Sales ($bn), 2011-2012
Table 7.5 Novartis Oncology Pipeline, 2012
Table 7.6 Celgene Anti-Cancer Drugs: Sales ($bn), 2011-2012
Table 7.7 Celgene Oncology Pipeline, 2012
Table 7.8 AstraZeneca Anti-Cancer Drugs: Sales ($bn), 2011-2012
Table 7.9 Selected Drugs from AstraZeneca Oncology Pipeline, 2012
Table 7.10 Eli Lilly Anti-Cancer Drugs: Sales ($bn), 2011-2012
Table 7.11 Selected Drugs from Eli Lilly Oncology Pipeline, 2012
Table 7.12 Merck & Co. Anti-Cancer Drugs: Sales ($bn), 2011-2012
Table 7.13 Merck & Co. Oncology Pipeline, 2012
Table 8.1 Cancer Medicines in Testing: Numbers by Therapeutic Area, 2012
Table 8.2 Bladder Cancer: Some Late Stage Drugs Under Development, 2012
Table 8.3 Brain Cancer: Some Late Stage Drugs Under Development, 2012
Table 8.4 Breast Cancer: Some Late Stage Drugs Under Development, 2012
Table 8.5 Cervical Cancer: Some Late Stage Drugs Under Development, 2012
Table 8.6 Colorectal Cancer: Some Late Stage Drugs Under Development, 2012
Table 8.7 Kidney Cancer: Some Late Stage Drugs Under Development, 2012
Table 8.8 Leukaemia: Some Late Stage Drugs Under Development, 2012
Table 8.9 Liver Cancer: Some Late Stage Drugs Under Development, 2012
Table 8.10 Lung Cancer: Some Late Stage Drugs Under Development, 2012
Table 8.11 Lymphoma: Some Late Stage Drugs Under Development, 2012
Table 8.12 Multiple Myeloma: Late Stage Drug Under Development, 2012
Table 8.13 Ovarian Cancer: Some Late Stage Drugs Under Development, 2012
Table 8.14 Pancreatic Cancer: Some Late Stage Drugs Under Development, 2012
Table 8.15 Prostate Cancer: Some Late Stage Drugs Under Development, 2012
Table 8.16 Sarcoma: Some Late Stage Drugs Under Development, 2012
Table 8.17 Skin Cancer: Some Late Stage Drugs Under Development, 2012
Table 8.18 Stomach Cancer: Some Late Stage Drugs Under Development, 2012
Table 8.19 Other Cancers: Some Late Stage Drugs Under Development, 2012
Table 9.1 SWOT Analysis of the Anti-Cancer Drugs Market, 2013
Table 9.2 STEP Analysis of the Anti-Cancer Drug Market, 2013
Afinitor (Novartis) – A Breast Cancer Breakthrough
Afinitor (everolimus) is an anti-neoplastic drug that targets the mTOR protein, which is a type of protein kinase that has a role to play in cellular proliferation and the growth of blood vessels. By blocking the action of mTOR, Afinitor prevents the growth of tumours and the blood vessels that supply them. It has been approved to treat post-menopausal women with Hormone Receptor+/HER2- advanced breast cancer. In addition, it is also used to treat metastatic pancreatic neuroendocrine tumours where the cells are well differentiated. Lastly, it is used to treat RCC in patients who have been previously treated with VEGF-targeting medicines, such as Avastin,Votrient or Sutent.
Afinitor Sales, 2012 – Another Success
Afinitor’s sales in 2012 were $0.8bn, which is represents an increase of 81.82% over the 2011 sales figure of $0.44bn. Sales were driven primarily by approval in the US and EU for the most common form of advanced breast cancer, HR+/HER2- advanced breast cancer. Table 5.42 and Figure 5.20 show Afinitor’s sales from 2011.
Competition Facing Afinitor
Afinitor faces competition from a number of products, such as these:
- Torisel (Pfizer): $0.37bn in sales in 2012
- Nexavar (Bayer/Onyx Pharmaceuticals): $1.02bn in sales in 2012.
Visiongain expects Afinitor to perform well over the forecast period because it was recently approved for the most common type of breast cancer, in both the US and EU, which afflicts 220,000 women annually. In addition, Afinitor is the first major breakthrough in the treatment of this disease for 15 years.
Afinitor’s first patents begin to expire in the US in 2016, and so generic competition will only become established after this date. In addition, since Afinitor is a conventional pharmaceutical product and not a biologic, visiongain expects it to come under severe pressure from generic alternatives not long after the expiry of its patents.
